EMEA-000308-PIP02-11-M01
Key facts
Invented name |
MabThera
|
Active substance |
rituximab
|
Therapeutic area |
Oncology
|
Decision number |
P/0060/2016
|
PIP number |
EMEA-000308-PIP02-11-M01
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of microscopic polyangiitis
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Roche Registration Limited
|
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000308-PIP02-11-M01
|
Compliance opinion date |
01/02/2019
|
Compliance outcome |
positive
|